- Category
- Micro (2024-25)
- Udyam number
- UDYAM-AP-10-0014406

Oxygeneca Labs Private Limited
About Oxygeneca Labs Private Limited
Data last updated:
Oxygeneca Labs Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 31 January 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24100TG2019PTC130194.
The company has an authorised share capital of ₹7.5 Cr and a paid-up capital of ₹6.3 Cr. It is led by directors Nitin Mukiri and Vanajakshi Sreerama.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 16 – 11 – 16/N/115 Teegalguda Saleemnagar Malakpet, Hyderabad, Telangana, India – 500036.
As per MCA filings, the company has open charges of ₹16 Cr on record. Court records list 1 case involving the company, including 1 filed against it; 1 case is pending.
Oxygeneca Labs Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-AP-10-0014406). The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Recognitions & Rankings of Oxygeneca Labs
Contact details
Oxygeneca Labs Private Limited's registered office is in Hyderabad, Telangana. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address16 – 11 – 16/N/115 Teegalguda Saleemnagar Malakpet, Hyderabad, Telangana, India – 500036
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Oxygeneca Labs Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Oxygeneca Labs is hospital and medical care. In detail, this covers other hospital and medical care activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q6 | Other Hospital and Medical Care Activities |
To see the full business activity and turnover split of Oxygeneca Labs Private Limited, buy the company report.
Financials of Oxygeneca Labs Private Limited
FY 2024 filings availableFinancial Statement Summary
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ||||
| Other Income | ||||
| Total Revenue | ||||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | ||||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | ||||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | ||||
| Net Profit Margin | ||||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of Oxygeneca Labs Private Limited, buy the company report.
Board of directors of Oxygeneca Labs Private Limited
Oxygeneca Labs has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Nitin Mukiri | Director | 31 Jan 2019 | 7 Years 9 Months | Current |
| Vanajakshi Sreerama | Director | 31 Jan 2019 | 7 Years 9 Months | Current |
Auditor
Oxygeneca Labs Private Limited is audited by M S P R & CO for the financial year 2022.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| M S P R & CO | FY 2022 | 010152S |
Shareholding
The shareholding of Oxygeneca Labs Private Limited is on record for 4 financial years, the latest being FY 2023, split between promoters, domestic institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Oxygeneca Labs Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 20 Apr 2022 | 100574616 | Karnataka Bank Ltd. | ₹16 Cr | Open |
To see the full charge records of Oxygeneca Labs Private Limited, buy the company report.
Total charge records: 1 View all charges
Legal cases
Oxygeneca Labs Private Limited has 1 court case on record: 1 filed against it. All case is pending.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 1 | 1 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Guntur, Andhra Pradesh | Criminal complaint | Filed against the company by an individual | Pending |
To see the full case history of Oxygeneca Labs Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Oxygeneca Labs Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Oxygeneca Labs Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Oxygeneca Labs Private Limited has 2 board changes on record since 2019: 2 appointments. The latest: Nitin Mukiri was appointed as Director on 31 Jan 2019.
Frequently asked questions
Oxygeneca Labs is an active private limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 31 January 2019 (7+ years old) and is registered under CIN U24100TG2019PTC130194.
Oxygeneca Labs has 2 current directors:
- Nitin Mukiri - Director
- Vanajakshi Sreerama - Director
The latest financial statements of Oxygeneca Labs on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from FY 2019 are in the company report.
The CIN (Corporate Identification Number) of Oxygeneca Labs is U24100TG2019PTC130194. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Oxygeneca Labs has 1 court case on record: 1 filed against it. 1 is pending.
Oxygeneca Labs was incorporated on 31 January 2019, making it 7+ years old. It is registered with the Registrar of Companies, Hyderabad.
Nitin Mukiri was appointed as Director on 31 Jan 2019. Vanajakshi Sreerama was appointed as Director on 31 Jan 2019.
Yes, Oxygeneca Labs is registered as a micro enterprise under Udyam registration (number: UDYAM-AP-10-0014406).
The registered office of Oxygeneca Labs is at 16 – 11 – 16N115 Teegalguda Saleemnagar Malakpet, Hyderabad, Telangana, India – 500036.
Oxygeneca Labs operates in the pharma industry, in the drug formulation and development segment.

